Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NPS Pharmaceuticals has reached an agreement with Allergan to promote Restasis, the first and currently only prescription eye drop to increase tear production in patients with chronic dry eye disease.
Subscribe to our email newsletter
Chronic dry eye disease is a common condition characterized by insufficient tear production to lubricate the eye frequently affecting patients with autoimmune disorders.
Under the agreement Allergan will supply product, promotional materials, training and other support to NPS rheumatology sales professionals who will promote Restasis ophthalmic emulsion exclusively to rheumatologists in the US for a period of four years starting November 2005.
The promotion of Restasis ophthalmic emulsion strengthens the relationships that NPS is building within the rheumatology community in preparation for the launch of Preos, the company’s proprietary drug candidate for the treatment of osteoporosis which is under review by the FDA.
Allergan will continue to promote the product to ophthalmologists and optometrists through its sales force and its extensive direct to consumer advertising, while NPS will support Allergan’s promotional efforts through sales and marketing activities directed to rheumatologists.
The agreement with Allergan is expected to generate additional revenue for Restasis. NPS will share in that revenue by receiving a percentage of the incremental sales generated through its promotional activities.
“This agreement represents continuing implementation of our commercial development plan. It expands our product line in rheumatology and gives us an important new product to offer rheumatologists and their patients with chronic dry eye disease,” said Dr Hunter Jackson, president of NPS.